

Press Release

Revenue up by 25% and PAT up by 31%

(1st Quarter FY 2027 Consolidated Results)

Mumbai, 30th July, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 1st quarter ended 30th June 2026.

Shareholders pay-out:

Today Board of Directors have approved interim dividend of Rs. 32 per share for face value of Rs. 2 per share amounting to Rs. 400 cr.

Q1 FY 2027 performance highlights (compared to Q1 FY 2026):

- Revenue from operations at **Rs. 1,626 cr.** against Rs. 1,303 cr.; **up 25%**.
- Adjusted EBITDA (excluding forex loss) at **Rs. 454 cr. & 28%** against Rs. 377 cr., up 21%.
- Profit after tax at **Rs. 334 cr.** against Rs. 255 cr.; PAT at 21%; **up 31%**.
- ROCE stood at a healthy level of 37% and RONW at 28%.

Segment wise performance:

(Rs. cr.)

Markets	Q1		Gwth%
	FY 2026	FY 2027	
Branded Generics			
India	₹ 409	₹ 509	24%
Asia	₹ 304	₹ 255	(16%)
Africa	₹ 228	₹ 295	30%
Sub-Total	₹ 941	₹ 1,059	13%
US Generic	₹ 310	₹ 487	57%
Africa Institution	₹ 38	₹ 70	83%
Total	₹ 1,289	₹ 1,616	25%

As per **IQVIA MAT June 2026**, our India branded generic performance exceeded IPM growth by **36%**. The higher growth came from new launches, which exceeded IPM by **76%** & volumes, which exceeded IPM by **40%**.

India branded generic Segment wise performance as per **IQVIA MAT June 2026** against IPM is as below:

Therapy	Growth %	
	IPM	Ajanta
Cardiology	15%	9%
Ophthalmology	10%	15%
Dermatology	8%	14%
Pain Management	10%	15%
Overall	11%	15%

ANDA status as at the end of Q1 FY 2027 is as below:

Particulars	Q1 FY 2027
Filed	-
Approval received	3
Launched	2
Total ANDA's commercialized	51
Awaiting approval with US FDA	17
Tentative approval	5

R&D expense:

(Rs. cr.)

Particulars	FY 2026	FY 2027	% to Revenue
Q1	₹ 56	₹ 66	4%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 33+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 16:15 hrs. IST (18:45 hrs. SST/HKT, 11:45 hrs. BST, 06:45 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	July 30, 2026 at 16:15 – 17:15 hrs IST 18:45 – 19:45 hrs SST/HKT 11:45 – 12:45 hrs BST 06:45 – 07:45 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

For convenience and faster connectivity to the conference, kindly follow below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

Safe Harbour Statement